# Zota Health Care share price today (Zota Health Care Ltd, NSE: ZOTA) > Zota Health Care share price today: ₹1,314.50 at the NSE close on 18 November 2026, down 22.0% in a year. Zota Health Care (NSE: ZOTA) is worth ₹4,553 crore, trades at a P/E of 327.0 and has closed between ₹1,060.50 and ₹1,685.10 over the past 52 weeks. > Zota Health Care Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ZOTA · Pharmacy Distribution · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/zota-health-care-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Price: ₹1,314.50 (−22.0% in a year) - P/E: 327.0× (higher than 80% of the last 3.7 years) - Revenue (Sep 2026): ₹199 Cr (+54.3% on a year ago) - Profit (Sep 2026): −₹26.0 Cr - Operating margin: 1.5% (−3.2 points on a year ago) - ROCE: −8%, FY26 - ROIC: −12.5%, against a 12.0% cost of capital: −24.5 points - Profit that came in as cash: 89%, last 3 years Biggest thing to watch: the P/E is higher than 80% of its own history, so the multiple has already done part of the work. ## What is the Zota Health Care share price today? Zota Health Care Ltd's share price was ₹1,314.50 at the close on 18 November 2026. It has been falling for 11 weeks. That is 4.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,061 and ₹1,685, and at that close it sat 41% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 3 weeks in a row. Over the last 9.5 years the share price moved +1,346% while the NIFTY 500 moved +186%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Zota Health Care this quarter? 4 points on a year earlier. 1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹199 crore, +54.3% on a year earlier. Why: Sales rose because Davaindia, its pharmacy chain, sold much more and made up most of revenue. Next results: check whether store openings restart in the second half as planned. From the earnings call on 29 Oct 2026. 2. Highest quarterly revenue in 16 quarters Revenue of ₹199 crore in the September 2026 quarter is the highest of the last 16 quarters. Why: The record quarter came because Davaindia, its pharmacy chain, sold much more and made up most of revenue. From the earnings call on 29 Oct 2026. 3. Operating margin down 3.4 points on a year earlier 1.5% in the September 2026 quarter, from 4.9%. Why: The company kept less from each sale after running costs because raw material costs jumped due to the war. Next results: check whether the share of sales left after medicine costs starts to recover as planned price rises come through. From the earnings call on 29 Oct 2026. ## What are Zota Health Care's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Zota Health Care reported revenue of ₹199 crore, up 54.3% from ₹129 crore a year earlier, and a loss of ₹26.0 crore. ### Zota Health Care results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹199 crore | ₹129 crore | +54.3% | | Profit | loss of ₹26.0 crore | loss of ₹16.0 crore | n/a | | Earnings per share | ₹−7.39 | ₹−5.20 | n/a | | Operating margin | 1.5% | 4.7% | −3.2 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Zota Health Care's management discussed these results on a call held on 29 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Zota Health Care share price history? Zota Health Care closed at ₹1,314.50 on 18 November 2026, down 22.0% from ₹1,685.10 a year earlier (21 November 2025) and up 241.2% over five years. Its highest weekly close since May 2017 was ₹1,685.10 on 21 November 2025. ### Zota Health Care share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹1,324.00 | −0.7% | | 1 month ago · 19 Oct 2026 | ₹1,359.90 | −3.3% | | 6 months ago · 15 May 2026 | ₹1,207.80 | +8.8% | | 1 year ago · 21 Nov 2025 | ₹1,685.10 | −22.0% | | 3 years ago · 17 Nov 2023 | ₹420.90 | +212.3% | | 5 years ago · 18 Nov 2021 | ₹385.30 | +241.2% | | Earliest and lowest weekly close in our records · 12 May 2017 | ₹90.89 | +1,346.3% | | Highest weekly close since May 2017, also the 52-week high · 21 Nov 2025 | ₹1,685.10 | −22.0% | | 52-week low (weekly close) · 27 Mar 2026 | ₹1,060.50 | +24.0% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (502 weekly closes from 12 May 2017 to 18 November 2026.) ## What is the latest news on Zota Health Care? 18 Nov 2026: Zota Health Care closed at ₹1,314.50, down 0.7% on the week and down 3.3% on the month. 29 Oct 2026: Zota Health Care held its results call for July to September 2026. Management guided: Second-half addition of 400-450 stores toward full-year plan following deliberate Q2 moderation. ### Earlier - Results for July to September 2026: Revenue up 54.3% on a year earlier. - 21 Sep 2026: ex-date for a dividend of ₹1 a share. ## What dividend does Zota Health Care pay? Zota Health Care paid ₹1 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.08% at the ₹1,314.50 close on 18 November 2026. The last was a dividend of ₹1 a share, ex-date 21 September 2026. ### Zota Health Care dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 21 Sep 2026 | ₹1 | Dividend | same day | | 22 Sep 2025 | ₹1 | Dividend | same day | | 20 Sep 2024 | ₹1 | Dividend | 21 Sep 2024 | | 22 Sep 2023 | ₹1 | Dividend | n/a | | 19 Sep 2022 | ₹1.50 | Dividend | n/a | | 22 Sep 2021 | ₹1 | Dividend | n/a | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record Not in its latest year. Zota Health Care Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 6 of its last 12 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Zota Health Care management say on the latest results call? On the call for July to September 2026, held on 29 October 2026, Zota Health Care's management guided: Second-half addition of 400-450 stores toward full-year plan following deliberate Q2 moderation. > “You can see that if we do not open new stores in the next 2 quarters, this loss of 12 crores will clearly become EBITDA positive.” > Himanshu Zota, on the call for July to September 2026 ### What management guided - FY27 total 600-650 stores including 200 opened in Q1 stake prior plan despite pause. - FY28 opening of 800 stores signalling renewed acceleration pace led by COCO format. - Pause-driven breakeven with all cohorts to store-positive within 2 quarters absent new opens. - New-store maturity accelerating to 12-15 months from 15-18 months on brand-density synergies. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/30201-29-Oct-2026.pdf). (From the call for July to September 2026, 29 October 2026.) ## What to watch in Zota Health Care's next results? When Zota Health Care reports October to December 2026, these are the 2 checks that show whether the story is still on course. First: Pre-Ind AS operating loss conversion on pause toward flagged breakeven and cohort positivity check - per management no-new-store math. Management raised each of these on the latest results call. - Pre-Ind AS operating loss conversion on pause toward flagged breakeven and cohort positivity check - per management no-new-store math. - Gross margin return toward prior band on annual hike cycle after war-driven surge - per management input-pressure timeline. ## Which stock lists is Zota Health Care on? Zota Health Care is on one of our India lists: Pharma stocks. [Pharma stocks Market value: ₹4,469 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is Zota Health Care profitable? Zota Health Care Ltd posted a net loss of ₹26.0 Cr in the Sep 2026 quarter. The full FY26 year was a loss of ₹74.0 Cr. The Sep 2026 quarter's loss is 13.1% of that quarter's revenue. The same quarter a year earlier lost ₹16.0 Cr. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Zota Health Care make, and is it growing? Zota Health Care Ltd reported ₹199 Cr of revenue in the Sep 2026 quarter, +54.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 14 years it has grown 20.8% a year on average. The last full year, FY26, came in at ₹538 Cr. The last four reported quarters add to ₹679 Cr. FY26 revenue was ₹538 Cr, +84.2% on the year before. Recent pace: the last four quarters grew +72.0% on average, against 20.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +68.9%, against +75.7% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does Zota Health Care keep? Zota Health Care Ltd's operating margin was 1.5% in the Sep 2026 quarter, 3.2 percentage points lower than the same quarter a year ago. Across 12 years it has been between −2.1% and 16.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −3.4 percentage points on the year while gross margin changed +0.8 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Zota Health Care's profit turning into cash? Over the last 3 years, 89% of Zota Health Care Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 its operations used ₹82.0 Cr of cash, against −₹74.0 Cr of profit. After ₹126 Cr of spending on assets, free cash was −₹208 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 89% of profit came in as cash: the cash cycle got 37 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Zota Health Care's cash go? Zota Health Care Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 198 days in FY26, up from 161 days in FY21. It spent ₹189 Cr on assets over the last 3 years. Customers take 50 days to pay, and stock sits for 324 days on average. At FY26 sales of ₹538 Cr, each day of that cycle ties up about ₹1.5 Cr, so roughly ₹292 Cr is tied up in the business at any time. FY26: customers took 50 days to pay and stock sat for 324 days, about 10.7 months of sales sitting as stock, for a full cycle of 198 days, longer than FY21's 161. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 324 days. Customers pay about 50 days after that. Suppliers are paid at 176 days. Together that makes the 198-day cycle. Spending on assets: ₹189 Cr over the last 3 years, against ₹145 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹15.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Zota Health Care's P/E ratio, and how does it compare with its own history? Zota Health Care Ltd's P/E is 327.0×, near the high end of its own history: higher than 80% of past readings. Its usual P/E (the middle reading) is 128.5×, over 3.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 3 years the price moved +46.2% a year; about −24.8% a year came from earnings growth and about +71.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Zota Health Care business getting better or worse? Zota Health Care Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Zota Health Care earn on its capital? Zota Health Care Ltd earned a ROCE of −8% in FY26. That is up from a low of −17% in FY25. Its return on capital used (ROIC) is 24.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −13.8% net margin and 0.48× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −13.8% net margin × 0.48× asset turnover × 1.63× leverage (assets divided by equity) ≈ −10.8% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −12.5% − 12.0% = −24.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −12.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at −10.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Zota Health Care have too much debt? Zota Health Care Ltd has total debt of ₹271 Cr against shareholder equity of ₹626 Cr as of Sep 2026, so its debt is 0.43× its equity. Year by year, that ratio went from 0.17 in FY22 to 0.39 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Zota Health Care shareholding pattern? Promoters cut their stake in Zota Health Care Ltd by 13.0 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 49.4% of the company. Foreign institutions moved +6.9 points over the same period, to 6.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −13.0 points over 8 quarters, to 49.4%; Foreign institutions: +6.9 points over 8 quarters, to 6.9%; Domestic institutions: +6.3 points over 8 quarters, to 7.3%. Why the owners changed: promoters drove it (−13.0 points), with the other side taken by foreign institutions (+6.9 points). They reduced their stake. ## How far is Zota Health Care from balance-sheet trouble? For Zota Health Care Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Zota Health Care rank in its industry? 31.4 out of 100, rank 3 of 5 in Pharmacy Distribution, with 56% of the evidence available. Zota Health Care Ltd scores 31.4 out of 100 against the 5 companies it is compared with in Pharmacy Distribution, ranking 3. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 12 + 1.3 + 10 + 8.1 = 31.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Zota Health Care compared with? Zota Health Care ranks 3 of 5 Pharmacy Distribution companies on the 4-Factor Sector Score, with 31.4 out of 100. 1. [Entero Healthcare Solutions Ltd](https://www.sectoralpha.in/stocks/entero-healthcare-solutions-ltd) ENTERO · leader · Most evidence points up · 72% evidence 69.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.9/35 · Revenue 34.7% · Profit 51.2% · Operating margin change 1 points · 95% evidence Capital efficiency 14.2/25 · ROCE 10.5% (year to Mar 2026) · Operating margin 5.3% · 76% evidence Valuation 10.0/20 · P/E 62× · PEG n/a · 0% evidence Relative strength 20.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 49.2% · Strength vs NIFTY 500 (same reading) 46.1% · 1 year 87% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.9 + 14.2 + 10 + 20 = 69.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Medplus Health Services Ltd](https://www.sectoralpha.in/stocks/medplus-health-services-ltd) MEDPLUS · basing · Evidence leans down · 90% evidence 36.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 20.6% · Profit 8.2% · Operating margin change -1 points · 100% evidence Capital efficiency 18.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 8.3% · 100% evidence Valuation 5.0/20 · P/E 34.1× · PEG 3.85 · 50% evidence Relative strength 0.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -21.7% · Strength vs NIFTY 500 (same reading) -23.5% · 1 year -21.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 18.1 + 5 + 0 = 36.4 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 3. Zota Health Care Ltd this page ZOTA · turning · Too little evidence to rank firmly · 56% evidence 31.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 68.9% · Profit -80% · Operating margin change -3.4 points · 74% evidence Capital efficiency 1.3/25 · ROCE -8.5% (year to Mar 2026) · Operating margin 1.5% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 8.1/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -3.7% · 1 year -22% · 25% evidence · 4 of 12 weeks ahead Exact sum: 12 + 1.3 + 10 + 8.1 = 31.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 4. [Health X Platform Ltd](https://www.sectoralpha.in/stocks/health-x-platform-ltd) HEALTHX · quiet · Too little evidence to rank firmly · 49% evidence 46.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.9/35 · Revenue 41.6% · Profit -80% · Operating margin change 3.4 points · 71% evidence Capital efficiency 7.3/25 · ROCE 0% (year to Mar 2026) · Operating margin -4.5% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 7.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) -10.8% · 1 year n/a · 25% evidence · 1 of 12 weeks ahead Exact sum: 21.9 + 7.3 + 10 + 7.5 = 46.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [Sastasundar Ventures Ltd](https://www.sectoralpha.in/stocks/sastasundar-ventures-ltd) SASTASUNDR · Too little evidence to rank firmly · 36% evidence 41.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/43.75 · Revenue 8.8% · Profit 100% · Operating margin change 5.4 points · 33% evidence Capital efficiency 8.0/31.25 · ROCE -1.3% (year to Mar 2025) · Operating margin -3% · 71% evidence Valuation 9.3/25 · P/E 33.6× · PEG n/a · 35% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 24.2 + 8 + 9.3 = 41.5 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharmacy Distribution](https://www.sectoralpha.in/sectors/pharmacy-distribution), all 5 compared on one page. ## Which companies are close to Zota Health Care in size? Zota Health Care is the 3rd largest of 5 Pharmacy Distribution companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Entero Healthcare Solutions and Medplus Health Services. Just below it: Health X Platform and Sastasundar Ventures. ### Pharmacy Distribution companies close in size 1. [Entero Healthcare Solutions Ltd](https://www.sectoralpha.in/stocks/entero-healthcare-solutions-ltd) ₹8,652 crore 2. [Medplus Health Services Ltd](https://www.sectoralpha.in/stocks/medplus-health-services-ltd) ₹7,214 crore 3. Zota Health Care Ltd ₹4,552 crore 4. [Health X Platform Ltd](https://www.sectoralpha.in/stocks/health-x-platform-ltd) ₹874 crore 5. [Sastasundar Ventures Ltd](https://www.sectoralpha.in/stocks/sastasundar-ventures-ltd) ₹874 crore [All 5 Pharmacy Distribution companies, largest first](https://www.sectoralpha.in/sectors/pharmacy-distribution#all-companies) ### Companies close in size in other industries 1. [Valor Estate Ltd](https://www.sectoralpha.in/stocks/valor-estate-ltd) ₹4,569 crore · Realty - Construction & Contracting 2. [Canara Robeco Asset Management Company Ltd](https://www.sectoralpha.in/stocks/canara-robeco-asset-management-company-ltd) ₹4,567 crore · Finance - AMC 3. Zota Health Care Ltd ₹4,552 crore 4. [Jana Small Finance Bank Ltd](https://www.sectoralpha.in/stocks/jana-small-finance-bank-ltd) ₹4,528 crore · Banks - Small Finance 5. [Uflex Ltd](https://www.sectoralpha.in/stocks/uflex-ltd) ₹4,526 crore · Packaging - BOPP ## What else do people ask about Zota Health Care? ### What is Zota Health Care's share price today? Zota Health Care Ltd's share price is ₹1,314.50, −22.0% over the past year. The whole company is worth ₹4,553 Cr on the market. In the last 52 weeks it traded between ₹1,061 to ₹1,685; today it is 41% of the way up from the low, 4.5% above its 200-day average (as of 18 November 2026). ### What were Zota Health Care's latest quarterly results? Zota Health Care Ltd reported revenue of ₹199 Cr and a net loss of ₹26.0 Cr for the Sep 2026 quarter. Earnings per share were −₹7.39. The operating margin was 1.5%, 3.2 percentage points lower than a year earlier (as of 18 November 2026). ### What is Zota Health Care's market cap? Zota Health Care Ltd's market capitalisation is ₹4,553 Cr at a share price of ₹1,314.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Zota Health Care performing? Zota Health Care Ltd's share price has been falling for 11 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 3 weeks running. This describes what the data did, not a rating (as of 18 November 2026). ### Will Zota Health Care's share price go up? This page does not forecast Zota Health Care Ltd's share price. What it shows instead: the share price is ₹1,314.50, and it has been falling for 11 weeks. Its P/E of 327.0× is higher than 80% of its own last 4 years (as of 18 November 2026). ### Does Zota Health Care have too much debt? Zota Health Care Ltd has a moderate amount of debt: its debt is 0.39× its equity, and its operating profit is 1 times its interest bill. FY26 borrowings were ₹270 Cr against equity of ₹694 Cr. Keep that borrowing in mind when reading the returns on this page (as of 18 November 2026). ### Where is Zota Health Care in its business cycle? Zota Health Care Ltd's FY26 operating margin was 3.5%, against a 12-year range of −2.1% to 16.0%. The latest quarter was 1.5%, the low end of its own range, which is often where recoveries start. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Zota Health Care story? Biggest thing to watch: the P/E is higher than 80% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Zota Health Care a stock worth studying right now? What the numbers show: Zota Health Care Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a Zota Health Care share price forecast for 2026? What management itself guided: Second-half addition of 400-450 stores toward full-year plan following deliberate Q2 moderation. ## Lists - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.